Galectin Therapeutics Gets Patent for Use of GR-MD-02

Galectin Therapeutics (NASDAQ:GALT) obtains US patent for reducing inflammatory response.
As quoted in the press release:

The patent’s principal claims cover method of use for GR-MD-02 in a broad category of diseases in which there is an inflammatory response characterized by an increase in the enzyme inducible nitric oxide synthase (iNOS). The patent covers the reduction in iNOS by GR-MD-02 in a variety of diseases including autoimmune disease, neurodegenerative disease, cardiovascular disease, psoriasis, cutaneous and systemic lupus erythematosus, systemic sclerosis (scleroderma) and dermatitis. The patent coverage extends through 2032.

This latest patent extends Galectin’s already robust U.S. and international patent portfolio. Granted patents include composition of matter, process of manufacture, and various methods of use. The breadth of coverage for the patent portfolio includes; various types of organ fibrosis (liver, lung, kidney, and heart), non-alcoholic steatohepatitis, kidney disease, autoimmune disorders and cancer, including combination cancer immunotherapy.
“With this patent extending claims to a wide-range of diseases with an inflammatory response, we now have a broad range of patent coverage both for diseases in which we currently have developmental programs, as well as, potential areas of future investigation,” said Peter G. Traber, M.D., chief executive officer and chief medical officer of Galectin Therapeutics and inventor on the patent. “Our patent portfolio is an important asset for Galectin Therapeutics. Each patent and patent application is a strategic building block which reflects present and future business objectives and protects current core technology. Galectin Therapeutics has multiple additional US and international patent applications pending.”

Click here to read the full press release.

Source: globenewswire.com